Related Experiment Videos
Workshop on growth factors
D Crowther1, M B Sporn, A B Roberts
1Christie Hospital, Manchester, UK.
Abstract:
The 'Workshop on Growth Factors' which took place at the Lugano Lymphoma Conference on June 8, 1990, included a presentation by Michael Sporn on the concept that loss of inhibitory control mechanisms may be important in the development and growth of human cancer. Examples illustrating this were taken from current experimental biology research into transforming growth factor beta (TGF-beta) interactions. Brian Durie presented recent data on the biology of interleukin-6 (IL-6) and its putative role in plasma cell diseases. These studies have culminated in the first clinical study of the role of an antibody to a growth factor as therapy for a human cancer (anti-IL-6 antibody as therapy for patients with myeloma). Derek Crowther presented data concerning the current clinical role of the haematopoietic growth factors in patients undergoing chemotherapy for cancer. Recent clinical research has established the role of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in improving the safety of high-dose or accelerated chemotherapy, and their use is associated with enhanced neutrophil recovery following ablative therapy and bone marrow rescue. This session was followed by the presentation of three papers concerning the use of G-CSF and GM-CSF in association with chemotherapy for patients with malignant lymphoma.
Insights
Growth factors like TGF-beta and IL-6 are crucial in cancer development and treatment. Research explores antibodies and hematopoietic growth factors (G-CSF, GM-CSF) to combat human cancers, including myeloma and lymphoma.
Area of Science:
- Oncology and Experimental Biology
- Immunology and Cancer Therapeutics
Background:
- Discusses the role of growth factors in human cancer development, focusing on the loss of inhibitory control mechanisms.
- Highlights transforming growth factor beta (TGF-beta) interactions and interleukin-6 (IL-6) in plasma cell diseases.
Framework:
- Explores the biological functions of IL-6 and its potential therapeutic targeting in myeloma.
- Introduces the concept of using antibodies against growth factors as a novel cancer therapy.
Implementation:
- Presents the first clinical study using an anti-IL-6 antibody for myeloma treatment.
- Details the clinical application of hematopoietic growth factors, including G-CSF and GM-CSF, in chemotherapy.
Implications:
- Demonstrates the efficacy of G-CSF and GM-CSF in improving neutrophil recovery and safety during high-dose chemotherapy.
- Suggests potential applications of G-CSF and GM-CSF in conjunction with chemotherapy for malignant lymphoma patients.